Submit abstracts for the 2020 Young Investigator Symposium by Sept. 9
Fall 2020 Group Meeting to be virtual
Funding is available for research pilot projects through the Cancer Control and Outcomes Program. Letters of intent due Sept 1. Applications due Sept. 15. Details here (member login required). Questions? Send an email
View the July Member Newsletter
View the ECOG-ACRIN Health Equity Inaugural Meeting webcast
NCI-ComboMATCH laboratory applications due Sept. 30
In case you missed it, the Q2 TMIST Study Updates Newsletter
Read our Advocacy Blog posts on treatment de-escalation
Question about COVID19? Send an email
Results of the EA5161 trial are “striking ASCO 2020 data” and significant for patients with extensive small-cell lung cancer because adding nivolumab improved progression-free and overall survival. August 5, 2020, OncLive
In the latest NCI-MATCH news, April K.S. Salama, MD, and colleagues report that the combination of dabrafenib and trametinib elicited favorable response rates. This promising activity warrants more investigations in BRAFV600-mutated tumors outside of currently approved indications. August 13, 2020, OncLive
Black Scientists Still Face an Uphill Battle in Securing NIH Research Grants: an interview with Edith P. Mitchell, MD (Thomas Jefferson U). “What we have to do is work in all areas and that’s what we’re doing in the ECOG-ACRIN Cancer Research Group, where I am a member of the executive committee.” July 15, 2020, Philadelphia Magazine
Taofeek Owonikoko, MD, PhD, MSCR (Emory U) on the results of trial EA5161: “Could there be unique differences between anti-PD-L1 and anti-PD-1 drugs? Possibly, however, I don’t think we can claim that such unique differences are significant enough to impact the efficacy of each in small-cell lung cancer.” July 15, 2020, Physician’s Weekly
Surprising Results from the PALLAS Trial: a discussion with Kathy D. Miller, MD (Indiana U). “More than anything else, this trial reminds us of the absolute necessity of putting our ideas to the test and doing appropriately powered, appropriately controlled, and well-conducted randomized trials.” July 1, 2020, Medscape
Study Shows Better Option for Treatment of Inoperable Anal Cancer: an article featuring Cathy Eng, MD (Vanderbilt U), lead investigator for InterAAct (EA2133), the first international prospective, randomized trial for advanced anal cancer. June 24, 2020, Science Magazine
Looking for more (older) news coverage? Visit the News and Info section and the TMIST Press Center.
View our YouTube channel for these and other videos: